Sucampo Pharma Llc Drug Patent Portfolio
Sucampo Pharma Llc owns 2 orange book drugs protected by 20 US patents Given below is the list of Sucampo Pharma Llc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8026393 | Soft-gelatin capsule formulation | 25 Oct, 2027 | Active |
US8338639 | Soft-gelatin capsule formulation | 23 Jan, 2027 | Active |
US8779187 | Soft-gelatin capsule formulation | 23 Jan, 2027 | Active |
US8748481 | Method for treating gastrointestinal disorder | 01 Sep, 2025 | Active |
US7795312 | Method for treating abdominal discomfort | 17 Sep, 2024 | Expired |
US6982283 | Method for treating drug-induced constipation | 04 Dec, 2022 | Expired |
US8097653 | Dosage unit comprising a prostaglandin analog for treating constipation | 14 Nov, 2022 | Expired |
US8389542 | Dosage unit comprising a prostaglandin analog for treating constipation | 14 Nov, 2022 | Expired |
US7064148 | Chloride channel opener | 30 Aug, 2022 | Expired |
US6458836 | Treatment of ocular hypertension and glaucoma | 09 Jul, 2021 | Expired |
US8088934 | Composition and method for stabilizing the same | 18 May, 2021 | Expired |
US6583174 | Composition and method for stabilizing the same | 16 Oct, 2020 | Expired |
US7417067 | Composition and method for stabilizing the same | 16 Oct, 2020 | Expired |
US8097649 | Composition and method for stabilizing the same | 16 Oct, 2020 | Expired |
US6414016 | Anti-constipation composition | 05 Sep, 2020 | Expired |
US8071613 | Anti-constipation composition | 05 Sep, 2020 | Expired |
US8114890 | Anti-constipation composition | 05 Sep, 2020 | Expired |
US6770675 | Compositions and methods for reducing ocular hypertension | 24 Nov, 2018 | Expired |
US5284858 | Prostaglandins E and anti ulcers containing same | 14 Jul, 2014 | Expired |
US5221763 | Prostaglandins of the F series | 15 Jul, 2012 | Expired |
Latest Legal Activities on Sucampo Pharma Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sucampo Pharma Llc.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jun, 2024 | US8338639 (Litigated) |
Expire Patent
Critical
| 08 Jan, 2024 | US8071613 |
Payment of Maintenance Fee, 12th Year, Large Entity | 14 Aug, 2023 | US8114890 |
Maintenance Fee Reminder Mailed
Critical
| 24 Jul, 2023 | US8071613 |
Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2023 | US8097649 |
Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2023 | US8097653 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 03 Jul, 2023 | US8088934 |
Payment of Maintenance Fee, 12th Year, Large Entity | 27 Mar, 2023 | US8026393 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 14 Mar, 2022 | US7795312 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2022 | US8779187 |
Payment of Maintenance Fee, 8th Year, Large Entity | 10 Dec, 2021 | US8748481 |
Payment of Maintenance Fee, 8th Year, Large Entity | 08 Sep, 2020 | US8389542 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2020 | US8338639 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 26 Feb, 2020 | US7417067 |
Payment of Maintenance Fee, 8th Year, Large Entity | 14 Aug, 2019 | US8114890 |
Sucampo Pharma Llc's Family Patents
Sucampo Pharma Llc Drug List
Given below is the complete list of Sucampo Pharma Llc's drugs and the patents protecting them.
1. Amitiza
Amitiza is protected by 17 patents, out of which 13 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8026393 | Soft-gelatin capsule formulation |
25 Oct, 2027
(2 years from now)
| Active |
US8338639 | Soft-gelatin capsule formulation |
23 Jan, 2027
(2 years from now)
| Active |
US8779187 | Soft-gelatin capsule formulation |
23 Jan, 2027
(2 years from now)
| Active |
US8748481 | Method for treating gastrointestinal disorder |
01 Sep, 2025
(8 months from now)
| Active |
US7795312 | Method for treating abdominal discomfort |
17 Sep, 2024
(3 months ago)
| Expired |
US6982283 | Method for treating drug-induced constipation |
04 Dec, 2022
(2 years ago)
| Expired |
US8097653 | Dosage unit comprising a prostaglandin analog for treating constipation |
14 Nov, 2022
(2 years ago)
| Expired |
US8389542 | Dosage unit comprising a prostaglandin analog for treating constipation |
14 Nov, 2022
(2 years ago)
| Expired |
US7064148 | Chloride channel opener |
30 Aug, 2022
(2 years ago)
| Expired |
US8088934 | Composition and method for stabilizing the same |
18 May, 2021
(3 years ago)
| Expired |
US6583174 | Composition and method for stabilizing the same |
16 Oct, 2020
(4 years ago)
| Expired |
US7417067 | Composition and method for stabilizing the same |
16 Oct, 2020
(4 years ago)
| Expired |
US8097649 | Composition and method for stabilizing the same |
16 Oct, 2020
(4 years ago)
| Expired |
US6414016 | Anti-constipation composition |
05 Sep, 2020
(4 years ago)
| Expired |
US8071613 | Anti-constipation composition |
05 Sep, 2020
(4 years ago)
| Expired |
US8114890 | Anti-constipation composition |
05 Sep, 2020
(4 years ago)
| Expired |
US5284858 | Prostaglandins E and anti ulcers containing same |
14 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amitiza's drug page
2. Rescula
Rescula is protected by 3 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6458836 | Treatment of ocular hypertension and glaucoma |
09 Jul, 2021
(3 years ago)
| Expired |
US6770675 | Compositions and methods for reducing ocular hypertension |
24 Nov, 2018
(6 years ago)
| Expired |
US5221763 | Prostaglandins of the F series |
15 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rescula's drug page